Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013  Joseph R. Mikhael, MD, David Dingli, MD, PhD, Vivek Roy, MD, Craig B. Reeder, MD, Francis K. Buadi, MD, Suzanne R. Hayman, MD, Angela Dispenzieri, MD, Rafael Fonseca, MD, Taimur Sher, MD, Robert A. Kyle, MD, Yi Lin, MD, PhD, Stephen J. Russell, MD, PhD, Shaji Kumar, MD, P. Leif Bergsagel, MD, Steven R. Zeldenrust, MD, PhD, Nelson Leung, MD, Matthew T. Drake, MD, PhD, Prashant Kapoor, MD, Stephen M. Ansell, MD, PhD, Thomas E. Witzig, MD, John A. Lust, MD, PhD, Robert J. Dalton, MD, Morie A. Gertz, MD, Keith Stewart, MBChB, S. Vincent Rajkumar, MD, Asher Chanan-Khan, MD, Martha Q. Lacy, MD  Mayo Clinic Proceedings  Volume 88, Issue 4, Pages 360-376 (April 2013) DOI: 10.1016/j.mayocp.2013.01.019 Copyright © 2013 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 1 Mayo Stratification of Myeloma and Risk-Adapted Therapy treatment algorithm for transplant-eligible patients. CR = complete remission; CyBorD = cyclophosphamide-bortezomib-dexamethasone; Rd = lenalidomide-dexamethasone; VRd = bortezomib-lenalidomidedexamethasone. Mayo Clinic Proceedings 2013 88, 360-376DOI: (10.1016/j.mayocp.2013.01.019) Copyright © 2013 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 2 Mayo Stratification of Myeloma and Risk-Adapted Therapy treatment algorithm for transplant-ineligible patients. CyBorD = cyclophosphamide-bortezomib-dexamethasone; MP = melphalan-prednisone; MPT = melphalan-prednisone-thalidomide; Rd = lenalidomide-dexamethasone; VRd = bortezomib-lenalidomide-dexamethasone. Mayo Clinic Proceedings 2013 88, 360-376DOI: (10.1016/j.mayocp.2013.01.019) Copyright © 2013 Mayo Foundation for Medical Education and Research Terms and Conditions